ColoGuidePro: A prognostic 7-gene expression signature for stage III colorectal cancer patients

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 6001-6010

  Sveen, Anita ^a,c   Ågesen, Trude H ^a,c   Nesbakken, Arild ^b,c   Meling, GunnIren ^f   Rognum, Torleiv O ^e   Liestlø, Knut ^c,d   Skotheim, Rolf I ^a,c   Lothe, Ragnhild A ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c Faculty of Medicine   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLASSIFIER; COLOGUIDEPRO; COLORECTAL CANCER; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NORWAY; NUCLEOTIDE SEQUENCE; ONSET AGE; POPULATION RESEARCH; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION; UNITED STATES; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TRANSCRIPTOME; WORKFLOW;

EID: 84868515495     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3302     Document Type: Article

References (39)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global cancer facts and figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Van Cutsem E, D'Hoore A, de Vleeschouwer C, Decaestecker J, Penninckx F. Colon cancer: management of locoregional disease. In:Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, Van Cutsem E, editors. Principles and practice of gastrointestinal oncology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 581.
3. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-9.
4. Andre T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006;13:887-98. (Pubitemid 43727375)
5. Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol 2006;7:515-6.
6. Kohne CH. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. Lancet Oncol 2006;7:516- 7.
7. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19. (Pubitemid 41103700)
8. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. (Pubitemid 38702845)
9. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5. (Pubitemid 39429665)
10. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Oncol Pract 2006;24:5313-27. (Pubitemid 46631379)
11. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278.
12. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-8. (Pubitemid 351264384)
13. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011;17:6012-20.
14. Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R, et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005;129:874-84. (Pubitemid 41242680)
15. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006;24:4685-90.
16. Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004;23:1377-91. (Pubitemid 38406833)
17. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005;23:3526-35.
18. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al. Gene expression pro files and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-71. (Pubitemid 41079793)
19. Lu AT, Salpeter SR, Reeve AE, Eschrich S, Johnston PG, Barrier AJ, et al. Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer 2009;8:207-14.
20. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res 2009;15:7642-51.
21. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937-44.
22. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
23. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010;138:958-68.
24. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J 2009;52:70-84.
25. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, et al.Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-52. (Pubitemid 24006146)
26. Berg M, Danielsen SA, Ahlquist T, Merok MA, Agesen TH, Vatn MH, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One 2010;5:e13978.
27. Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA, Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: associations with splicing factor expression levels and patient survival. Genome Med 2011;3:32.
28. Norwegian Directorate of Health. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i tykktarm og endetarm. Oslo, Norwegian Directorate of Health. 2012 Jun 28.
29. Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012 Jan 2. [Epub ahead of print].
30. van Houwelingen HC, Bruinsma T, Hart AA, van't Veer LJ, Wessels LF. Cross-validated Cox regression on microarray gene expression data. Stat Med 2006;25:3201-16. (Pubitemid 44377341)
31. Tibshirani R. Regression shrinkage and selection via the LASSO. J R Statist Soc B 1996;58:267-88.
32. Tibshirani R. The LASSO method for variable selection in the Cox model. Stat Med 1997;16:385-95. (Pubitemid 27073009)
33. NæsT, Mevik BH. Understanding the collinearity problem in regression and discriminant analysis. J Chemom 2001;15:413-26.
34. PARSC study (NCT00903565). A prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint (PARSC). 2010. [cited 2012 Sep 21]. Available from: http://clinicaltrials.gov/ct2/show/ NCT00903565.
35. Genomic Health I. Oncotype DX colon cancer assay. 2011. [cited 2012 Sep 21]. Available from: http://www.oncotypedx.com/en-US/Colon.aspx.
36. Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery IC, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;27:4000.
37. Webber EM, Lin JS, Evelyn PW. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr 2010;2:RRN1177.
38. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2010;2:14ps2.
39. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 2008;24:2200-8.